在非阻塞性冠状动脉疾病 (MINOCA) 的心肌梗塞中精确医学:综合性综述
Laveeza Fatima1, Aman Goyal2, Shreyas Yakkali3
1Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
Current problems in cardiology
|November 4, 2023
概括
带有非阻塞性冠状动脉的心肌梗塞 (MINOCA) 是一个诊断挑战. 基于MINOCA的量身定制的医疗管理
科学领域:
- 心脏病学 心脏病学
- 心血管医学 心血管医学
- 精准医学是一门精准的医学.
背景情况:
- 心肌梗塞 (MI) 是全球死亡的主要原因之一.
- 传统的MI诊断依赖于确定冠状动脉阻塞.
- 非阻塞性冠状动脉心肌梗塞 (MINOCA) 影响患者没有显著的阻塞,造成诊断挑战.
研究的目的:
- 为了突出MINOCA病例中的诊断困难.
- 强调在MINOCA诊断和管理中需要精准医学.
- 根据其根本原因,讨论针对MINOCA的量身定制的治疗策略.
主要方法:
- 在MINOCA的诊断挑战的审查.
- 讨论当前和新兴的诊断工具,包括成像技术.
- 基于MINOCA病理生理学的治疗策略的分析.
主要成果:
- 由于缺乏阻塞性冠状动脉病变,MINOCA诊断具有挑战性.
- 穿皮冠状动脉干预 (PCI) 不适用于MINOCA患者.
- 量身定制的医疗管理至关重要,根据原因而异 (例如,斑块破坏与冠状动脉).
结论:
- 有效的MINOCA管理需要个性化的治疗方法.
- 目前正在进行的研究重点是新的生物标志物,先进的诊断和MINOCA的个性化治疗.
- 了解特定的病理生理机制是MINOCA治疗成功的关键.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy III: Hypertrophic Cardiomyopathy
15
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
15
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Angina IV: Management
9
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
9
Acute Coronary Syndrome I: Introduction
30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30


